Biopharma leaders to reveal successful strategies for China, India at the PharmAsia Summit

October 13, 2010

San Francisco, Calif., 13 October, 2010 - Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and "The Pink Sheet," today announced the agenda for Windhover's 2nd PharmAsia Summit (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

At the PharmAsia Summit, you'll hear Asia strategies and case studies from industry leading experts on dealmaking, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include:Plus, you'll have a rare opportunity to speak with top Asia regulators, including:"PharmAsia Summit is a rare opportunity for U.S. biopharma execs to gain an insider's perspective on the most important developments in China, India and Japan without having to cross the Pacific," said Gerry Stoia, president of Elsevier Business Intelligence. "Given the increasing importance of markets like China and India to the biopharma industry, we are honored to host this distinguished group in San Francisco, and hope the Summit will contribute to the dialogue between U.S. and Asia biopharma leaders."

Attendees will in addition learn the latest on China healthcare reform, U.S. FDA actions in China and India, case studies on Japanese dealmaking with U.S. biotechs, novel Asia investment strategies, tips for launching innovative therapies in India and China, opportunities for pre-competitive collaboration that will help de-risk R&D, and finding the right partner in Asia.

Moreover, attendees will catch up on the latest Asian market trends and data from IMS Health, which sees China becoming the third largest pharma market in 2011 and predicts explosive growth in other hot Asia markets like India and Korea.
-end-
For further information: http://www.windhover.com/windhover/content/conferences/pharmasia.aspx.

About Windhover Conferences and Elsevier Business Intelligence

Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of "The Pink Sheet," PharmAsia News, "The Tan Sheet", IN VIVO: The Business & Medicine Report, Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access, Elsevier and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit www.ElsevierBI.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including the Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier

Related Case Studies Articles from Brightsurf:

Every COVID-19 case seems different; these scientists want to know why
As scientists around the world develop life-saving COVID-19 vaccines and therapies, many are still wondering exactly why the disease proves deadly in some people and mild in others.A new international study led by scientists at La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton is the first to give a detailed snapshot of how the body's CD4+ T cells respond to the SARS-CoV-2 virus.

Too many COVID-19 patients get unneeded 'just in case' antibiotics
More than half of patients hospitalized with suspected COVID-19 in Michigan during the state's peak months received antibiotics soon after they arrive, just in case they had a bacterial infection in addition to the virus, a new study shows.

AI with 'imagination' could help doctors with diagnosis, particularly for complex case
Babylon has built Artificial Intelligence with 'imagination' that could soon help doctors with diagnosis, particularly for complex cases.

Plant-based diets high in carbs improve type 1 diabetes, according to new case studies
Plant-based diets rich in whole carbohydrates can improve insulin sensitivity and other health markers in individuals with type 1 diabetes, according to two case studies published by researchers from the Physicians Committee for Responsible Medicine in the Journal of Diabetes & Metabolism.

Quantitative reconstruction of formation paleo-pressure and case studies
As the paleo-pressure is significant for hydrocarbon accumulation and reservoir formation, geologists are eager for an accurate reconstruction of paleo-pressure, although that is very hard.

The case for economics -- by the numbers
In recent years, criticism has been levelled at economics for being insular and unconcerned about real-world problems.

Case management in primary care associated with positive outcomes
In a systematic review, researchers identified three characteristics of case management programs that consistently yielded positive results: case selection for frequent users with complex problems, high-intensity case management interventions and a multidisciplinary care plan.

The case for retreat in the battle against climate change
With sea level rise and extreme weather threatening coastal communities, it's no longer a question of whether they are going to retreat; it's where, when and how.

Case studies suggest that 'red flag' laws play a role in preventing mass shootings
Case studies of individuals threatening mass violence suggest that extreme risk protection orders (ERPOs), colloquially known as 'red flag' orders, may play a role in preventing mass shootings.

Making a case for returning airships to the skies
Reintroducing airships into the world's transportation-mix could contribute to lowering the transport sector's carbon emissions and can play a role in establishing a sustainable hydrogen based economy.

Read More: Case Studies News and Case Studies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.